Evidence map›Paper›PMID 41050242›Full record

ArticleActa clinica Croatica2024

RELATIONSHIP OF IMMUNOHISTOCHEMICAL EXPRESSION OF CD86/CD163 POSITIVE INTRATUMORAL MACROPHAGES WITH PROGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA.

Goran Glavčić, Mario Zovak, Slavica Sović, Silvija Mašić, Nina Blažević, Zvonimir Misir, Zdenko Bilić, Marin Glavčić, Petra Radulović

Abstract read
In one paragraph

Article in Acta clinica Croatica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Goran GlavčićDepartment of Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Mario ZovakDepartment of Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Slavica SovićSchool of Medicine, University of Zagreb, Zagreb, Croatia.
Silvija MašićLjudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Nina BlaževićDepartment of Internal medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Zvonimir MisirDepartment of Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Zdenko BilićDepartment of Surgery, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.
Marin GlavčićDepartment of Surgery, Dubrava University Hospital, Zagreb, Croatia.
Petra RadulovićLjudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent studies have shown an association of the number of tumor-associated macrophages (TAM) with the prognosis and treatment outcomes of ductal pancreatic adenocarcinoma. This study aimed to examine the correlation between CD86 and CD163 macrophage expression and clinical-pathological characteristics of the disease in patients operated on for pancreatic carcinoma. A retrospective research was conducted in which the archival materials of the Ljudevit Jurak Department of Pathology, Sestre milosrdnice University Hospital Center were used together with all relevant patient clinical data obtained from the Hospital Information System on 76 patients operated on for pancreatic adenocarcinoma. In our study, the number of CD86 macrophages and the CD86/CD163 ratio showed a statistically significant correlation with increasing T and N stages of the disease. The number of CD163 macrophages did not show a statistically significant correlation with the mentioned variables. These results indicated that in our clinical conditions, proinflammatory (M1) macrophages were more expressed in locally advanced tumor stages with worse long-term prognoses. In conclusion, TAMs could be a valid prognostic marker or even a target for therapeutic agents but more studies will be needed to fully comprehend the impact of M1/M2 differentiation.

Indexed as

Antigens, CDAntigens, Differentiation, MyelomonocyticB7-2 AntigenCarcinoma, Pancreatic DuctalMacrophagesPancreatic NeoplasmsReceptors, Cell SurfaceTumor-Associated MacrophagesAdultAgedAged, 80 and overCD163 AntigenFemaleHumansImmunohistochemistryMaleAntigens, CDAntigens, Differentiation, MyelomonocyticB7-2 AntigenCD163 AntigenReceptors, Cell SurfaceCancer researchCD68/CD163M1/M2 macrophagesPancreatic adenocarcinomaSurgical oncologyTumor-associated macrophages

Identifiers

PMID41050242
PMCPMC12490443

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.